High-performance liquid chromatography (HPLC) testing has become an essential quality control requirement for 503B outsourcing facilities under the Drug Quality and Security Act (DQSA). As FDA oversight of outsourcing facilities has intensified, the expectation that every pharmaceutical compound — including diluents like bacteriostatic water for injection — be accompanied by HPLC purity data has become standard practice rather than best practice.
Why HPLC Testing Is Critical for 503B Facilities
Under 21 CFR Part 212, 503B outsourcing facilities are required to comply with cGMP regulations for drug manufacturers — including rigorous quality control testing of raw materials, in-process materials, and finished products. For pharmaceutical water used as a vehicle, diluent, or ingredient in sterile compounded preparations, HPLC testing verifies chemical purity, identifies potential impurities, and confirms batch-to-batch consistency.
The Role of Certificate of Analysis Documentation
FDA inspectors examining 503B facilities routinely review supplier COAs for pharmaceutical water and other raw materials. A comprehensive COA should include HPLC purity results with method references, endotoxin testing data (LAL method), microbiological testing results, pH, conductivity, and all relevant physical and chemical parameters. Renew Lab Group provides exactly this documentation with every order — designed to withstand FDA inspection scrutiny.
Contact Renew Lab Group today to discuss pharmaceutical-grade bacteriostatic water supply agreements for your 503B facility: 936-379-5515.
